GCC Global Announces Appointment of New Director

Vancouver, British Columbia–(Newsfile Corp. – December 31, 2018) – GCC Global Capital Corporation (TSXV: GCCC) (the “Company”) is pleased to announce the appointment of Ms. Qianying Zhou to its Board of Directors effective today. Ms. Zhou has over ten years of working experience in financial services. Ms. Zhou is currently holding a Senior Account Manager position with Business Development Bank of Canada and provides financing and advisory services to technology companies in the west coast of Canada. Between 2015 and 2017, Ms. Zhou worked with PricewaterhouseCooper LLP as Corporate Finance Manager. From July 2014 to September 2015, Ms. Zhou worked with London Life-Great-west Lifeco Inc as Financial Security Advisor. From 2008 to 2012, Ms. Zhou worked with Royal Bank of Canada as Senior Account Manager. Ms. Zhou holds a Bachelor of Commerce degree from the University of British Columbia in Vancouver British Columbia and she is also a CFA (Chartered Financial Analyst) charter holder.

About GCC Global Capital Corporation

GCC Global Capital Corporation is listed on the TSX Venture Exchange as an Investment Issuer. The Company focuses on Real Estate, Natural Resources and High-Tech industries.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

For further information please contact Andrew Liu, Chief Financial Officer at (778) 389-9960.

Advertisements

CardioComm Solutions’ HeartCheck CardiBeat FDA 510(k) Review Extended

FDA Removes Additional Clinical Testing Requirements for the HeartCheck CardiBeat

Toronto, Ontario–(Newsfile Corp. – December 31, 2018) – CardioComm Solutions, Inc. (TSXV: EKG) (“CardioComm” or the “Company“), a leading global provider of consumer heart monitoring and electrocardiogram (“ECG“) acquisition and management software solutions, confirms the USA Food and Drug Administration (“FDA“) has reduced the scope of their request for additional information for the Company’s premarket notification 510(k), Class II medical device clearance application for the HeartCheck™ CardiBeat and GEMS™ Mobile Application.

CardioComm submitted its most recent 510(k) application to the FDA for Class II Medial device clearance on the HeartCheck™ CardiBeat as previously reported. The Company was then requested by the FDA to provide additional data that included clinical evaluations to confirm the device’s ability to record ECGs equivalent to those using conventional ECG electrode patches and ECG cables.

Subsequent to receiving the Company’s reply with additional data, the FDA provided guidance on two primary items. These were:

  1. the Company no longer was required to support the request for extensive ECG electrode testing data; and,
  2. additional data was requested related to Bluetooth wireless coexistence testing.

In compliance to the FDA’s directive, the Company has submitted a letter of revocation of their supplementary information submission which was accepted by the FDA on December 26, 2018. The Company will provide the FDA a restatement of their response for additional information to the FDA by January 23, 2019 without clinical ECG testing data and with the requested wireless coexistence data. The FDA will have 31 days to complete the 510(k) review following receipt of CardioComm’s restated submission.

The Company will provide updates on this and future 510(k) applications. To learn more about CardioComm’s products and for further updates regarding HeartCheck™ ECG device integrations please visit the Company’s websites at www.cardiocommsolutions.com and www.theheartcheck.com.

About CardioComm Solutions
CardioComm Solutions’ patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485:2016 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425 x227
egrima@cardiocommsolutions.com

investor.relations@cardiocommsolutions.com

Forward-looking statements
This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management’s current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Osprey Closes Flow Through Private Placement for Proceeds of $100,050

Vancouver, British Columbia–(Newsfile Corp. – December 31, 2018) – OSPREY GOLD DEVELOPMENT LTD. (TSXV: OS) (OTCQB: OSSPF) (the “Company” or “Osprey”) is pleased to report that it has closed its previously announced non-brokered private placement (the “Private Placement”) of 1,334,000 flow through units (FT Units) of Osprey at a price of $0.075 per unit, for aggregate proceeds of $100,050. Each unit consists of one common share and one-half of one share purchase warrant, each whole warrant entitling the holder to purchase an additional common share at a price of $0.12 per share for a period of 18 months from date of issuance.

The net proceeds of the private placement will be used for exploration and advancement of Osprey’s exploration projects located in Nova Scotia, Canada, and general working capital. All securities issued under the Private Placement are subject to a hold period expiring four months and one day after date of issuance.

The Company paid aggregate cash finders’ fees of $7,004 and issued 93,380 Finders’ Warrants in connection with the Private Placement. Each Finder’s Warrant entitles the holder to acquire one common share of the Company at $0.12 per share for 18 months from the date of closing.

About Goldenville and Osprey

Osprey is focused on exploring five historically producing gold properties in Nova Scotia, Canada. Osprey has the option to earn 100% (subject to certain royalties) in all five properties, including the Goldenville Gold Project, Nova Scotia’s largest historic gold producer. Goldenville hosts a current NI 43-101 Inferred Resource of 2,800,000 tonnes at 3.20 g/t gold for 288,000 ounces of gold (2,800,000 tonnes at 4.96 g/t gold for 447,000 ounces of gold uncapped) near the town of Sherbrooke, NS. All five properties in Osprey’s current portfolio have a history of high-grade gold production. A copy of the Company’s technical report titled “Technical Report on the Goldenville Property, Guysborough County, Nova Scotia Canada” prepared by David G. Thomas, M.Sc., P. Geo. and Neil Pettigrew, M.Sc., P. Geo. is available under the Company’s profile at www.sedar.com.The technical information in this release has been reviewed and approved by the Company’s Vice President of Exploration Perry MacKinnon, P.Geo, a ‘Qualified Person’ under NI 43-101.

Additional information regarding Osprey and the Goldenville property is available under the Company’s profile at www.sedar.com and at www.ospreygold.com.

ON BEHALF OF OSPREY GOLD DEVELOPMENT LTD.,

Cooper Quinn

Cooper Quinn, President and Director

For further information please contact Osprey at (778)986-8192 or cooper@ospreygold.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to Osprey within the meaning of applicable securities laws and with respect to the financing and the properties. Osprey provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited to, exploration findings, results and recommendations, as well as those risks and uncertainties identified and reported in Osprey’s public filings under Osprey’s SEDAR profile at www.sedar.com. Although Osprey has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Osprey disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

UNITED STATES ADVISORY. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), have been offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS.

CORRECTION FROM SOURCE: Cardero Closes Private Placement

Vancouver, British Columbia–(Newsfile Corp. – December 31, 2018) – Cardero Resource Corp. (TSXV: CDU) (FSE: CR5) (OTCBB: CDYCF) (“Cardero” or the “Company”) reports that pursuant to the news release dated December 28, 2018 and the closing of the private placement the Company confirms that on November 9, 2018, the Company issued 300,000 units at a price of $0.10 per Unit for aggregate proceeds of $30,000. All other information pursuant to the closing remain unchanged. The Company further notes that cash finder’s fees were paid to Haywood Securities Inc.

ABOUT CARDERO RESOURCE CORP.

The common shares of the Company are currently listed on the TSX Venture (symbol CDU) and the Frankfurt Stock Exchange (symbol CR5). For further details on the Company readers are referred to the Company’s web site (www.cardero.com), Canadian regulatory filings on SEDAR at www.sedar.com and United States regulatory filings on EDGAR at www.sec.gov.

On Behalf of the Board of Directors of

CARDERO RESOURCE CORP.

“Stuart Ross” (signed)

Stuart Ross, CEO and President

Contact Information:

Stuart Ross,
604 408 7488 Ext. 3883

General Contact:

Email: info@cardero.com
Toll Free: 1-888-770-7488
Tel: 604 408-7488
Fax: 604 408-7499

Cautionary Note Regarding Forward-Looking Statements

Forward Looking Information: This news release includes certain information that may be deemed “forward looking information”. Forward-looking information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. All information in this release, other than information of historical facts, including, without limitation, the availability of financing to the Company are forward-looking information that involve various risks and uncertainties. Although the Company believes that the expectations expressed in such forward-looking information are based on reasonable assumptions, such expectations are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking information. Forward-looking information is based on a number of material factors and assumptions. Factors that could cause actual results to differ materially from the forward-looking information include changes in project parameters as plans continue to be refined, future metal prices, availability of capital and financing on acceptable terms, general economic, market or business conditions, regulatory changes, delays in receiving approvals, and other risks detailed herein and from time to time in the filings made by the Company with securities regulatory authorities in Canada. Mineral exploration and development of mines is an inherently risky business. Accordingly, actual events may differ materially from those projected in the forward-looking information. For more information on the Company and the risks and challenges of our business, investors should review our continuous disclosure filings which are available at http://www.sedar.com. Readers are cautioned not to place undue reliance on forward-looking information. The Company does not undertake to update any forward looking information, except in accordance with applicable securities laws.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

-30-

White Metal Closes $180,000 Financing

Thunder Bay, Ontario–(Newsfile Corp. – December 31, 2018) –  White Metal Resources Corp. (TSXV: WHM) (“White Metal” or the “Company”) is pleased to announce that the Company has closed its previously announced financing, subject to Toronto Venture Exchange approval.

The Company has raised $180,000 by issuing 3,600,000 Flow-Through Units (FT Units) at $0.05 per FT Unit, each FT Unit consisting of 1 common flow-through share and one (1) common share purchase warrant, each warrant (a “Warrant”) being exercisable for one common share of the Company at $0.15 for a period 24 months from the date of issuance of such Warrants, subject to the right of the Company to accelerate the exercise period of the Warrants if the price of shares of the Company closes at or above $0.30 for 30 consecutive trading days. All securitis issued pursuant to this financing will be subject to a 4 month hold period. A cash finder’s fee of $4,900 was paid in respect of this financing.

The Placement was effected with an insider of the Company subscribing for 1,800,000 FT Units for aggregate subscription proceeds of $90,000, that portion of the financing a “related party transaction” as such term is defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying on exemptions from the formal valuation and minority approval requirements set out in MI 61- 101. The Company is exempt from the formal valuation requirement of MI 61-101 under sections 5.5(a) and (b) of MI 61-101 in respect of the transaction as the fair market value of the transaction, insofar as it involves the interested party, is not more than the 25% of the Company’s market capitalization. Additionally, the Company is exempt from minority shareholder approval under sections 5.7(1)(a) and (b) of MI 61-101 as, in addition to the foregoing, (i) neither the fair market value of the Units nor the consideration received in respect thereof from interested party exceeds $2,500,000, (ii) the Company has one or more independent directors who are not employees of the Company, and (iii) all of the independent directors have approved the transaction. Material change reports were not filed 21 days prior to the closing of the financing because insider participation had not been established at the time the financing was announced.

About White Metal Resources Corp. (TSX-V: WHM)
White Metal Resources Corp is a junior exploration company exploring in Canada.

On behalf of the Board of Directors of White Metal Resources Corp.

“Jean-Pierre Colin”
Jean-Pierre Colin, President, CEO and Director

For further information contact:

Jean-Pierre Colin
President, CEO & Director
(416) 573-4300
jpcolin.whitemetal@gmail.com

or

Michael Stares
Director
84 Squier Street
Thunder Bay, Ontario, Canada, P7B 4A8
Phone: (807) 628-7836

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Sokoman Iron Closes Non-brokered Flow-Through Private Placement

St. John’s, New Foundland–(Newsfile Corp. – December 31, 2018) – Sokoman Iron Corp. (TSXV: SIC) (OTCQB: SICNF) (‘Sokoman’ or ‘the Company’) is pleased to announce that the TSX Venture Exchange has accepted for filing documents to close a flow-through, non-brokered private placement (the “Placement”) for total proceeds of $1,175,000 consisting of 5,875,000 Flow-Through Units (the “FT Units”) at a price of $0.20 per FT Unit. Each FT Unit consists of one flow-through common share and one-half of a common share purchase warrant. Each full warrant is exercisable into one common share at a price of 35 cents per share for a period of 18 months from closing.

All securities issued pursuant to the Placement are subject to a 4-month hold period. The finder’s fees associated with the transaction were $46,500. The proceeds of the financing will be used to advance the Company’s flagship Moosehead Gold Project.

Tim Froude, President and CEO of Sokoman stated: “It is most gratifying to start the New Year with a top up of our treasury made possible by several flow-through funds, Mr. Eric Sprott, other insiders and some investment advisors. We have an aggressive drill program planned to begin in January once we have received, studied and press released the balance of the assays from our Phase 2 Program at our Moosehead gold property in Central Newfoundland.”

The Placement was effected with insiders of the Company subscribing for 1,375,000 FT Units for aggregate subscription proceeds of $275,000, that portion of the financing a “related party transaction” as such term is defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company is relying on exemptions from the formal valuation and minority approval requirements set out in MI 61- 101. The Company is exempt from the formal valuation requirement of MI 61-101 under sections 5.5(a) and (b) of MI 61-101 in respect of the transaction as the fair market value of the transaction, insofar as it involves the interested party, is not more than the 25% of the Company’s market capitalization. Additionally, the Company is exempt from minority shareholder approval under sections 5.7(1)(a) and (b) of MI 61-101 as, in addition to the foregoing, (i) neither the fair market value of the Units nor the consideration received in respect thereof from interested party exceeds $2,500,000, (ii) the Company has one or more independent directors who are not employees of the Company, and (iii) all of the independent directors have approved the transaction. Material change reports were not filed 21 days prior to the closing of the financing because insider participation had not been established at the time the financing was announced.

Eric Sprott acquired 1,250,000 FT Units pursuant to the Placement. Prior to the Placement, Mr. Sprott owned 13,350,000 common shares and 13,350,000 common share purchase warrants of the Company representing approximately 13.4% of the issued and outstanding common shares of the Company on a non-diluted basis and 23.7% on a partially diluted basis. As a result of the Placement, Mr. Sprott is the owner of 14,600,000 common shares and 13,975,000 common share purchase warrants of the Company representing approximately 14.7% of the issued and outstanding common shares of the Company on a non-diluted basis and 25.2% on a partially diluted basis. The above percentages are calculated based on 99,308,809 common shares issued and outstanding after giving effect to the Placement.

The FT Units were acquired by Mr. Sprott for investment purposes. Mr. Sprott has a long-term view of the investment and may acquire additional securities of the Company either on the open market or through private acquisitions or sell securities of the Company either on the open market or through private dispositions in the future depending on market conditions, reformulation of plans and/or other relevant factors. A copy of Mr. Sprott’s early warning report will appear on the Company’s profile on SEDAR and may also be obtained by calling (416) 362-7172 (200 Bay Street, Suite 2600, Royal Bank Plaza, South Tower, Toronto, Ontario M5J 2J2).

About Sokoman Iron Corp.

Sokoman Iron Corp. (TSXV: SIC) is a discovery-focused company with projects in Newfoundland & Labrador, Canada. Sokoman’s primary focus is its portfolio of gold projects in Central Newfoundland. The Company also has interests in early-stage gold, base-metal and antimony projects in Newfoundland, as well as a 100% interest in the Iron Horse (Fe/V/REE) project in Western Labrador.

To learn more, please contact:

Timothy Froude, P. Geo.,
President & CEO
709-765-1726
tfroude@sokomaniron.com

Cathy Hume,
Investor Relations
416-868-1079
cathy@chfir.com

Website: www.sokomaniron.com
Twitter: @SokomanIron
Facebook: @SokomanIron

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements:

Investors are cautioned that trading in the securities of the Corporation should be considered highly speculative. Except for historical information contained herein, this news release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially. Sokoman Iron Corp. will not update these forward-looking statements to reflect events or circumstances after the date hereof. More detailed information about potential factors that could affect financial results is included in the documents filed from time to time with the Canadian securities regulatory authorities by Sokoman Iron Corp.

Cell MedX Corp. Enters into Credit Line Agreement and Issues Warrants

Carson City, Nevada–(Newsfile Corp. – December 31, 2018) – Cell MedX Corp. (OTCQB: CMXC) (“Cell MedX” or the “Company”), an early development stage bio-tech company focusing on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness, announces that on December 27, 2018, the Company entered into an Agreement with Mr. Richard Jeffs (the “Lender”), the Company’s major shareholder (the “Agreement”), for an unsecured line of credit of up to USD$250,000 (the “Credit Line”) of which USD$100,000 was advanced to the Company on December 20, 2018.

Under the Agreement Cell MedX may borrow against the Credit Line and repay any portion of the amount borrowed at any time. The funds advanced under the Credit Line accumulate interest at a rate of 6% per annum. In consideration for the Credit Line the Company issued to the Lender non-transferable share purchase warrants (the “Warrants”) to purchase up to 5,000,000 shares of Cell MedX’s common stock exercisable at USD$0.05 per share and expiring on December 27, 2021. The Warrants vest at a rate of 20 warrants for every USD$1 drawn on the Credit Line, with 2,000,000 warrants having vested on the grant date of the Warrants on account of USD$100,000 advance noted above.

In addition, in recognition of USD$124,128 previously advanced by the Lender, the Company issued to the Lender non-transferable share purchase warrants (the “Additional Warrants”) to purchase up to 2,482,960 shares exercisable at USD$0.05 per share and expiring on December 27, 2021. The Additional Warrants vested at the time of grant.

The Credit Line shall be used for working capital and to increase the current inventory of eBalance devices as the Company moves toward commercialization.

For additional information regarding the Agreement and the Credit Line please refer to Form 8-K the Company filed with the Securities and Exchange Commission on December 31, 2018.

About Cell MedX Corp.

Cell MedX Corp. is an early development stage bio-tech company focused on the discovery, development and commercialization of therapeutic and non-therapeutic products that promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson’s disease, and high blood pressure. For moe information about the Company and its technology please visit our website at www.cellmedx.com/investors/overview/. For the Company’s newsletter please visit www.cellmedx.com/media/newsletters/.

On behalf of the Board of Directors of Cell MedX Corp.

Frank McEnulty

CEO, Director

Forward Looking Statements

The information included in this press release has not been reviewed by the FDA or Health Canada, nor has it been peer reviewed. This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as “expects”, “intends”, “estimates”, “projects”, “anticipates”, “believes”, “could”, and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company’s Quarterly, and Annual Reports filed with the United States Securities and Exchange Commission (the “SEC”). Should one or more of these risks or uncertainties materialize, or should any of the Company’s underlying assumptions prove incorrect, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company’s forward-looking statements. In particular, the Company’s eBalance technology is still in development. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.

SOURCE:
Cell MedX Corp.
For further information please visit: www.cellmedx.com
Toll free: 1.844.238.2692